{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:06:06Z","timestamp":1789664766455,"version":"4.0.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00433","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T04:55:22Z","timestamp":1585025722000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":55,"title":["Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders"],"prefix":"10.3389","volume":"11","author":[{"given":"Celine","family":"Kaegi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs C.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wuest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Boyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMra1100030","article-title":"Genomics and the multifactorial nature of human autoimmune disease","volume":"365","author":"Cho","year":"2011","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","article-title":"Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)","volume":"27","author":"Masters","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrrheum.2014.123","article-title":"Adverse reactions to biologic agents and their medical management","volume":"10","author":"Boyman","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.3389\/fimmu.2018.02698","article-title":"Inhibition of membrane-bound BAFF by the anti-BAFF antibody belimumab","volume":"9","author":"Kowalczyk-Quintas","year":"2018","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2147\/DDDT.S71276","article-title":"Profile of atacicept and its potential in the treatment of systemic lupus erythematosus","volume":"9","author":"Cogollo","year":"2015","journal-title":"Drug Des Dev Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"Brit Med J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community H"},{"key":"B11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jns.2015.02.019","article-title":"ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis","volume":"351","author":"Sergott","year":"2015","journal-title":"J Neurol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/art.30373","article-title":"Atacicept in patients with rheumatoid arthritis an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II. Randomized, placebo-controlled, dose-finding trial","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/art.23178","article-title":"Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study","volume":"58","author":"Tak","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/art.30372","article-title":"Atacicept in patients with rheumatoid arthritis an inadequate response to methotrexate: results of a phase II. randomized, placebo-controlled trial","volume":"63","author":"van Vollenhoven","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1002\/art.39262","article-title":"Safety efficacy of atacicept in combination with rituximab for reducing the signs symptoms of rheumatoid arthritis: a phase II. Randomized, double-blind, placebo-controlled pilot trial","volume":"67","author":"van Vollenhoven","year":"2015","journal-title":"Arthritis Rheum"},{"key":"B17","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0961203309102803","article-title":"An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus","volume":"18","author":"Pena-Rossi","year":"2009","journal-title":"Lupus"},{"key":"B19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheum."},{"key":"B20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs."},{"key":"B21","unstructured":"Efficacy and Safety of Atacicept in IgA Nephropathy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00433\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T04:55:25Z","timestamp":1585025725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00433\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2020.00433"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00433","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"article-number":"433"}}